| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 10/24/2013 | US20130280299 Viral vectors and their use in therapeutic methods |
| 10/24/2013 | US20130280242 Method of plscr inhibition for cancer therapy |
| 10/23/2013 | EP2653561A1 Ultraconserved regions encoding ncRNAs |
| 10/23/2013 | EP2653478A1 A novel antigen associated with the neovasculature of tumour metastases |
| 10/23/2013 | EP2653167A1 Cell migration modulator |
| 10/23/2013 | EP2653157A1 Astaxanthin for improving muscle atrophy |
| 10/23/2013 | EP2652506A2 The use anti-cxcl16 and anti-cxcr6 antibodies for the treatment or detecting cancer |
| 10/23/2013 | EP2652137A1 Lar protein-specific ligand |
| 10/23/2013 | EP2652136A1 Nucleic acids targeting tctp for use in the treatment of chemo-or hormone-resistant cancers |
| 10/23/2013 | EP2651978A1 Use of an antibody directed against a membrane protein |
| 10/23/2013 | EP2651976A1 Combination therapy of an afucosylated cd20 antibody with a mdm2 inhibitor |
| 10/23/2013 | EP2651951A1 Tricyclic pi3k inhibitor compounds and methods of use |
| 10/23/2013 | EP2651950A1 6 substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders |
| 10/23/2013 | EP2651949A1 Substituted pyrimido[1,2-b]indazoles and their use as modulators of the pi3k/akt pathway |
| 10/23/2013 | EP2651948A1 Imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment hyperproliferative disorders |
| 10/23/2013 | EP2651947A1 6-thio-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders |
| 10/23/2013 | EP2651946A1 2-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders |
| 10/23/2013 | EP2651945A1 6-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders |
| 10/23/2013 | EP2651944A1 Substituted 6-imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders |
| 10/23/2013 | EP2651939A1 SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS |
| 10/23/2013 | EP2651932A1 Bicyclic ring system substituted sulfonamide functionalised phenols as medicaments |
| 10/23/2013 | EP2651919A1 Dimeric iap inhibitors |
| 10/23/2013 | EP2651918A1 Crystalline forms of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine |
| 10/23/2013 | EP2651917A1 Dimeric iap inhibitors |
| 10/23/2013 | EP2651916A2 C-17-heteroaryl steroidal compounds as inhibitors of cyp11b, cyp17, and/or cyp21 |
| 10/23/2013 | EP2651898A1 Novel n- (4- (azetidine - 1 - carbonyl) phenyl) - (hetero - ) arylsulfonamide derivatives as pyruvate kinase m2 (pmk2) modulators |
| 10/23/2013 | EP2651894A1 Thiosemicarbazone compounds and use in the treatment of cancer |
| 10/23/2013 | EP2651864A1 Methods and devices for using isoperillyl alcohol |
| 10/23/2013 | EP2651444A1 Anthraquinones for use as radiosensitizers in cancer treatment |
| 10/23/2013 | EP2651443A2 Anti-ccl25 and anti-ccr9 antibodies for the prevention and treatment of cancer and cancer cell migration |
| 10/23/2013 | EP2651442A2 Universal anti-tag chimeric antigen receptor-expressing t cells and methods of treating cancer |
| 10/23/2013 | EP2651414A1 Combination therapy comprising vemurafenib and an interferon for use in the treatment of cancer |
| 10/23/2013 | EP2651412A2 Androgen receptor inhibitors and methods of use thereof |
| 10/23/2013 | CN103370414A Method for reducing expression of downregulated in renal cell carcinoma in malignant gliomas |
| 10/23/2013 | CN103370339A Multimeric il-15 soluble fusion molecules and methods of making and using same |
| 10/23/2013 | CN103370338A Myomegalin variant 8 and uses thereof |
| 10/23/2013 | CN103370334A Modified human tumor necrosis factor receptor-I polypeptide or fragment thereof and method for preparing same |
| 10/23/2013 | CN103370331A Amino statin derivatives for the treatment of arthrosis |
| 10/23/2013 | CN103370329A Amphiphilic cyclic phosphazene trimer, hydrophobic pharmaceutical formulation micellized by amphiphilic cyclic phosphazene trimer, and preparation methods thereof |
| 10/23/2013 | CN103370322A 2-substituted imidazopyrazines for use as MPS-1 and TKK inhibitors in the treatment of hyperproliferative disorders |
| 10/23/2013 | CN103370321A Substituted pyrimido[1,2-b]indazoles and their use as modulators of the PI3K/AKT pathway |
| 10/23/2013 | CN103370318A Substituted imidazopyridazines |
| 10/23/2013 | CN103370316A 3-aryl-6-aryl-[1,2,4]triazolo[4,3-a]pyridines as inhibitors of cell proliferation and the use thereof |
| 10/23/2013 | CN103370314A Substituted benzopyrazin derivatives as FGFR kinase inhibitors for the treatment of cancer diseases |
| 10/23/2013 | CN103370311A Pochoxime conjugates useful for the treatment of HSP90 related pathologies |
| 10/23/2013 | CN103370308A Thiosemicarbazone compounds and use in the treatment of cancer |
| 10/23/2013 | CN103370066A Combination therapy comprising vemurafenib and an interferon for use in the treatment of cancer |
| 10/23/2013 | CN103370060A Treatment of cancer/inhibition of metastasis |
| 10/23/2013 | CN103370054A Lipid formulated compositions and methods for inhibiting expression of EG5 and VEGF genes |
| 10/23/2013 | CN103369973A Novel use of maltotriosyl transferase |
| 10/23/2013 | CN103361424A MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors |
| 10/23/2013 | CN103361379A Construction, screening and application of shRNAs expression vector of lung cancer targeted CHRNA5 gene |
| 10/23/2013 | CN103361351A ShRNA of human RUNX2 gene, and recombinant interference vector and application thereof |
| 10/23/2013 | CN103361349A Application of BRSK2SR2 in preparation of medicines for inhibiting pancreatic cancer |
| 10/23/2013 | CN103361347A Micro RNA (Ribonucleic Acid) aiming at angiogenin 2 |
| 10/23/2013 | CN103361343A Application of BRSK2SR1 in preparation of medicines for inhibiting pancreatic cancer |
| 10/23/2013 | CN103360504A Preparation method of bamboo fungus protein polysaccharide |
| 10/23/2013 | CN103360497A Novel antitumor fusion protein vaccine, and preparation method and application thereof |
| 10/23/2013 | CN103360496A Anti-EphB4 antibodies and methods of using these antibodies |
| 10/23/2013 | CN103360494A Completely anti-CD20 human monoclonal antibody and application thereof |
| 10/23/2013 | CN103360466A Composition of tumour-associated peptides and related anti-cancer vaccine |
| 10/23/2013 | CN103360465A HLA-A*0201 restricted CTL epitope of cytoplasmic polyadenylation element binding proteins (CPEBs) 4 and application thereof |
| 10/23/2013 | CN103360437A Lipoic acid saccharide derivatives as well as preparation method and application thereof in preparation of anti-tumor drugs |
| 10/23/2013 | CN103360428A Ruthenium-containing complex for inhibiting protein tyrosine phosphatase 1B activity as well as preparation method of complex and protein tyrosine phosphatase 1B inhibitor |
| 10/23/2013 | CN103360427A Three-nitrogen dynamic platinum compound as well as preparation method and application thereof |
| 10/23/2013 | CN103360426A Phosphoinositide compounds, as well as preparation method and application thereof |
| 10/23/2013 | CN103360423A Benzyltin aromatic aldehyde condensed arylamine Schiff base complex and its preparation method and application thereof |
| 10/23/2013 | CN103360407A Thiophene miazines derivate as well as preparation method and medical application thereof |
| 10/23/2013 | CN103360403A Compound having cytotoxicity, composition, and preparation method and use thereof |
| 10/23/2013 | CN103360399A 6-aryl-substituted-imidazole-[1,2-b]pyridazine derivative and preparation method and application thereof |
| 10/23/2013 | CN103360392A Dolasetron mesylate compound |
| 10/23/2013 | CN103360382A Quinazoline derivative and application thereof |
| 10/23/2013 | CN103360371A (E)-N-(2-amino-phenyl)-3-{1-[4-(1-methyl-1H-pyrazol-4-yl)-benzenesulfonyl]-1H-pyrrol-3-yl}-acrylamide salts |
| 10/23/2013 | CN103360358A 15-oxospiramilactone derivatives, and preparation method and applications thereof |
| 10/23/2013 | CN103360329A Phenazine compound and it application in preparation of anti-tumor drugs |
| 10/23/2013 | CN103360327A Benzophenazine derivative, as well as preparation method and application thereof |
| 10/23/2013 | CN103360317A Dicyclo-substituted pyrazolone azo derivatives, as well as preparation method and use thereof |
| 10/23/2013 | CN103360312A Geldanamycin derivative and its application |
| 10/23/2013 | CN103360276A Crystal form, preparation method and application of agomelatine, as well as medicine composition |
| 10/23/2013 | CN103359706A Preparation method and application of cationized magnetic carbon nano-tubes |
| 10/23/2013 | CN103357887A Sea urchin-shaped hollow gold and silver alloy nano particle and preparation method and application thereof |
| 10/23/2013 | CN103357027A Nanocapsule having MRI tracer effect |
| 10/23/2013 | CN103357025A Application of BRSK2 in preparation of medicines for inhibiting pancreatic cancer |
| 10/23/2013 | CN103357024A Liver cancer suicide gene therapy medicine based on aminated silicon dioxide nanoparticle-CD/TK (cytosine deaminase-thymidine kinase) fused gene compound |
| 10/23/2013 | CN103357023A Method for increasing solubility of 10-hydroxycamptothecin, product prepared by the method and applications of the product |
| 10/23/2013 | CN103357022A Bifunctional polyethylene glycol and adriamycin conjugate and preparation method thereof |
| 10/23/2013 | CN103357021A Pharmaceutical composition using albumin as pharmaceutical carrier |
| 10/23/2013 | CN103357013A Composition for enhancing bioavailability of taxane medicament |
| 10/23/2013 | CN103357012A Taxane self-emulsifying or self-microemulsifying drug transfer system and preparation method thereof |
| 10/23/2013 | CN103357008A Novel vaccine adjuvant based on bacillus calmette guerin-polysaccharide nucleic acid and application of novel vaccine adjuvant |
| 10/23/2013 | CN103357001A Preparation method of tumour antigen |
| 10/23/2013 | CN103356995A Hgf制剂 Hgf preparations |
| 10/23/2013 | CN103356973A Antineoplastic traditional Chinese medicine |
| 10/23/2013 | CN103356971A Traditional Chinese medicine composition capable of substantially improving human immunity and preparation method thereof |
| 10/23/2013 | CN103356969A Traditional Chinese medicine composition for treating hysteromyoma |
| 10/23/2013 | CN103356964A Medicament for treating ovarian cyst, and preparation method thereof |
| 10/23/2013 | CN103356957A Medicine for treating stomach cancer and preparation method thereof |
| 10/23/2013 | CN103356941A Health-care medicinal liquor having a plurality of functions |
| 10/23/2013 | CN103356940A Natural drug extract and its preparation method |
| 10/23/2013 | CN103356938A Natural pharmaceutical composition and preparation method thereof |